LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 1 of total 1

Search options

Article ; Online: Tolerated Re-Challenge of Immunotherapy in a Patient with ICI Associated Myocarditis: A Case Report and Literature Review.

Shalata, Walid / Attal, Zoé Gabrielle / Shhadi, Rajeh / Abu Salman, Amjad / Abu Jama, Ashraf / Shalata, Sondos / Halumi, Kais / Yakobson, Alexander

Medicina (Kaunas, Lithuania)

2023  Volume 59, Issue 11

Abstract: Many different types of cancer can be treated with immunotherapy drugs called immune checkpoint inhibitors (ICIs). These drugs have altered the landscape of cancer treatment options since they function by triggering a stronger immune response to ... ...

Abstract Many different types of cancer can be treated with immunotherapy drugs called immune checkpoint inhibitors (ICIs). These drugs have altered the landscape of cancer treatment options since they function by triggering a stronger immune response to malignancy. As expected, ICIs' modification of immune regulatory controls leads to a wide range of organ/gland-specific immune-related side effects. These adverse effects are uncommonly deadly and typically improve by discontinuing treatment or administering corticosteroid drugs. As a result of a number of factors-including a lack of specificity in the clinical presentation, the possibility of overlap with other cardiovascular and general medical illnesses, difficulties in diagnosis, and a general lack of awareness-the true incidence of ICI-associated myocarditis is likely underestimated. Currently, protocols for the surveillance, diagnosis, or treatment of this condition are unclear. Several questions remain unanswered, such as how to best screen for this rare toxin, what tests should be run on patients who are suspected of having it, how to treat myocarditis once it has developed, and who is at most risk. In this article, we provide a case study of ICI-associated myocarditis and explain its key characteristics and treatment options.
MeSH term(s) Humans ; Immunotherapy/adverse effects ; Myocarditis/chemically induced ; Myocarditis/therapy ; Neoplasms/therapy
Language English
Publishing date 2023-11-03
Publishing country Switzerland
Document type Case Reports ; Journal Article ; Review
ZDB-ID 2188113-3
ISSN 1648-9144 ; 1010-660X
ISSN (online) 1648-9144
ISSN 1010-660X
DOI 10.3390/medicina59111946
Shelf mark
Zs.A 6270: Show issues Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)
Database MEDical Literature Analysis and Retrieval System OnLINE

More links

Kategorien

To top